Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats

The Journal of Pharmacy and Pharmacology
Joelle de Melo TurnesMaria A B F Vital

Abstract

To determine whether the drug saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor which is utilized for the treatment of Diabetes Mellitus, has neuroprotective effects in the animal model of Parkinson's disease (PD) induced by 6-hydroxydopamine (6-OHDA) in rats. Male Wistar rats (weighing 280-300 g) received a bilateral infusion of 6-OHDA in the substantia nigra. Twenty-four hours later, they were treated with saxagliptin (1 mg/kg, p.o) once daily, for 21 days. The motor function was evaluated using the open field and rotarod (RT) tests. In addition, cognition was assessed with the novel object recognition test (ORT). After the evaluation of the behavioural tests, the animals were transcardially perfused to perform immunohistochemistry staining for tyrosine hydroxylase (TH) in the substantia nigra pars compacta (SNpc). Saxagliptin impaired the memory of animals in the sham group. Saxagliptin treatment did not exhibit neuroprotection and it did not improve the cognitive and motor deficits in the 6-OHDA model of PD. Interestingly, when saxagliptin was administered to the sham animals, a cognitive decline was observed. Therefore, this drug should be investigated as a possible treatment for PTSD.

References

Dec 1, 1974·Journal of Chronic Diseases·I J LipmanR E Flora
Nov 1, 1971·The Journal of Clinical Endocrinology and Metabolism·A E BoydJ M Feldman
Jan 26, 2007·Diabetes Care·Gang HuJaakko Tuomilehto
Feb 27, 2007·European Journal of Pharmacology·Angela B ReksidlerMaria A B F Vital
Apr 23, 2008·Current Protocols in Neuroscience·R J CarterS B Dunnett
Mar 8, 2011·Diabetes Care·Qun XuHonglei Chen
Apr 14, 2011·British Journal of Pharmacology·Susan Duty, Peter Jenner
Nov 24, 2011·Neuroscience·J Bové, C Perier
Jan 1, 2011·Clinical Medicine Insights. Endocrinology and Diabetes·Jay ShubrookFrank Schwartz
Nov 10, 2012·Expert Opinion on Drug Safety·Shamsa Ali, Vivian Fonseca
Nov 28, 2012·Nature Reviews. Neurology·Michel GoedertHeiko Braak
Dec 15, 2012·The Journal of Comparative Neurology·Guibao GuJoseph S Heilig
Feb 5, 2013·Trends in Molecular Medicine·Jose A Santiago, Judith A Potashkin
Apr 23, 2013·Neuropharmacology·Jayasankar KosarajuDuraiswamy Basavan
Sep 26, 2013·CNS & Neurological Disorders Drug Targets·Marcelo M S LimaAnete C Ferraz
Mar 7, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Janaína K BarbieroMaria A B F Vital
Aug 21, 2014·BioMed Research International·Na-Hyung KimDae Ho Lee
Aug 30, 2014·Behavioural Brain Research·Sarah J Cohen, Robert W Stackman
Nov 11, 2014·Expert Opinion on Pharmacotherapy·André J Scheen
Dec 3, 2014·Neuropharmacology·Noha N NassarDalaal M Abdallah
Dec 3, 2014·Journal of Pharmacological and Toxicological Methods·Yi HuanZhu-fang Shen
Sep 1, 2015·Journal of Emergency Nursing : JEN : Official Publication of the Emergency Department Nurses Association·Leslie C Rideout, Patricia A Normandin
Sep 19, 2015·Physiology & Behavior·Swati Jain, Bhupesh Sharma
Mar 13, 2016·Behavioural Brain Research·Akram NezhadiSaeed Esmaeili-Mahani
Jan 1, 2015·Nature Reviews. Disease Primers·Rachel YehudaSteven E Hyman
Sep 1, 2016·Journal of Neurochemistry·Wolfgang Oertel, Jörg B Schulz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.